The 5th iPSC Drug Development Summit serves as a pivotal platform for uniting iPSC-based drug developers across the value ...

XellSmart has completed multiple cases of iPSC-derived dopaminergic neural progenitor cell therapy for patients with ...

Explore the functional analysis of compound responses in iPSC-derived 3D cardiac microtissues for insights into cardiac ...

Laminin 521 (Cat. No. GMP-LA5H24) successfully maintained rapid expansion of human iPSCs, enabling cell passaging after just ...

As the first regenerative clinical trial globally employing a subtype-specific neural progenitor cell therapeutic product to ...

The partnership will integrate Molecular Health’s digital drug development platform into Axxam's integrated early drug ...

Fate Therapeutics, Inc. (NASDAQ:FATE) announced today that it will present groundbreaking clinical data from its Phase 1 ...

SUZHOU, China, June 2, 2025 /PRNewswire/ -- XellSmart Biomedical Co., Ltd. (Suzhou/Shanghai, China) is a leading biotechnology company dedicated to the development of innovative iPSC-derived cell ...

Trinity College Dublin is to divest from new arrangements with Israeli universities, firms and institutions. The board of the ...

The iPSC platform uses engineered master iPSC lines for uniform, off-the-shelf cellular immunotherapies that can be stored and administered easily. What unique technologies are highlighted in the ...